Cytodyn Inc (CYDY)

[shallwemaui]

I'm sticking to my guns. The first day we begin enrolling Stage iib patients, the value of Pro 140 as an HIV treatment should be in the 250 to 300 million range. The wildcard is uses of Pro 140 for things other than HIV. I spoke directly with Dr. Feigal on this subject at the shareholder meeting. I asked if there was a "quicker" path to FDA approval for one of the other treatment uses. Specifically, at that time I asked about Staph Infection uses. In the past month or so, we've seen data that indicates that CCR5 may be a key element in breast cancer. Wow. While I hope (every day) to see the announcement that begins our Stage iib testing at Drexel, we know it is inevitable that it comes, we just don't know which day. CYDY has announced a second study for treatment interruption. I believe, given the press coverage of breast cancer and CCR5, that CYDY will also announce a study of Pro 140 in breast cancer treatement. Combined, these things should push the stock price up near the $5 share that Stephanie Kramer forecasted, even with the recent dilution.